<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Hypomethylating agents have activity in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and have received approval for the treatment of both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The specific efficacy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> has not been detailed in a large number of patients </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of the study was to evaluate the activity and safety of <z:chebi fb="0" ids="50131">decitabine</z:chebi> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Nineteen adults with a diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> treated on <z:chebi fb="0" ids="50131">decitabine</z:chebi> studies were analyzed </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="50131">Decitabine</z:chebi> was given at 100 mg/m(2) per course every 4 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>The median number of courses given was 9 (range, 1-18) </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Overall, 11 patients (58%) achieved complete response (CR) and 2 (11%) had hematologic improvement (HI), for an overall response rate of 69% according to the modified International Working Group (IWG) criteria </plain></SENT>
<SENT sid="7" pm="."><plain>Median survival was 19 months </plain></SENT>
<SENT sid="8" pm="."><plain>Severe (grade 3-4) extramedullary side effects were rare </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="50131">Decitabine</z:chebi> is active in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Studies of combinations of <z:chebi fb="0" ids="50131">decitabine</z:chebi> with <z:chebi fb="0" ids="50276">topoisomerase I inhibitors</z:chebi> or other active anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> agents are indicated </plain></SENT>
</text></document>